FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to nephrology, and can be used to assess an individual's renal toxicity following administration of a compound that is suspected to cause the renal toxicity. The renal toxicity is determined by measuring an amount of a biomarker in the individual's urine sample and comparing the measured amount to the corresponding amount of the biomarker in a healthy individual. The renal toxicity represents varying or damaged glomeruli, while the biomarker is β-2-microglobulin protein. There are also presented a diagnostic technique or a method for prediction of the varying or damaged glomeruli, and a method for monitoring the effect of the renal toxicity treatment in the patient using the agent.
EFFECT: group of inventions provides reliable assessment of the renal toxicity in the patient by determining the specific and sensitive biomarker of the damaged glomeruli.
4 cl, 9 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| DIAGNOSTIC TECHNIQUE AND KIT FOR DIAGNOSING GLOMERULONEPHITIS IN CAT | 2011 |
|
RU2564122C2 |
| COMPOSITIONS, DIAGNOSTIC TECHNIQUES AND METHOD OF TREATING RENAL DISORDERS IN DOGS | 2010 |
|
RU2546016C2 |
| HUMANIZED MODEL OF KIDNEY AND LIVER DISORDERS | 2018 |
|
RU2772583C2 |
| COMPOSITIONS CONTAINING CELL VESICLES AND USE THEREOF | 2019 |
|
RU2824136C2 |
| ORGANOIDS CONTAINING ISOLATED RENAL CELLS, AND THEIR USE | 2014 |
|
RU2722361C2 |
| IMMUNOLOGICALLY PRIVILEGED BIOACTIVE KIDNEY CELLS FOR TREATMENT OF KIDNEY DISEASE | 2018 |
|
RU2816753C2 |
| DISEASE DIAGNOSTICS TECHNIQUE BY ORGANISM TISSUES, BLOOD OR LIQUIDS SCREENING IN ANIMAL OR HUMAN FOR NONPHYSIOLOGICAL HEPSIDIN LEVELS AND ITS THERAPEUTIC APPLICATION | 2003 |
|
RU2359268C2 |
| TREATING KIDNEY DISEASE IN SUBJECTS WITH RENAL AND/OR URINARY TRACT ABNORMALITIES | 2020 |
|
RU2823980C2 |
| METHOD FOR THE DIAGNOSIS AND/OR PROGNOSIS OF ACUTE RENAL DAMAGE | 2012 |
|
RU2657422C2 |
| RENAL CELL POPULATIONS AND THEIR USE | 2013 |
|
RU2805243C2 |
